Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Otlertuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Emergent Product Development Seattle
- 23 Mar 2012 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 23 Mar 2012 Actual patient number is 96 according to ClinicalTrials.gov.
- 23 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.